<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="682">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05152277</url>
  </required_header>
  <id_info>
    <org_study_id>HRS9531-101</org_study_id>
    <nct_id>NCT05152277</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HRS9531 in Healthy Subjects</brief_title>
  <official_title>A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single- and Multiple-Ascending Dose Study in Healthy Subjects to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous Administered HRS9531</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fujian Shengdi Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fujian Shengdi Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is being conducted to evaluate the safety, tolerability, pharmacokinetics, and&#xD;
      pharmacodynamics of single and multiple subcutaneous injections of HRS9531 in healthy&#xD;
      subjects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 5, 2021</start_date>
  <completion_date type="Anticipated">October 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>HRS9531 compared with placebo</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Adverse Events</measure>
    <time_frame>Start of Treatment to end of study (approximately 7 weeks or 9 weeks)</time_frame>
    <description>A summary of adverse events, including Serious Adverse Events(SAEs)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time curve (AUC) of HRS9531</measure>
    <time_frame>Start of Treatment to end of study (approximately 7 weeks)</time_frame>
    <description>AUC of HRS9531 after single subcutaneous injection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity qualitative</measure>
    <time_frame>Start of Treatment to end of study (approximately 7 weeks)</time_frame>
    <description>anti-HRS9531 antibody</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC of HRS9531</measure>
    <time_frame>Start of Treatment to end of study (approximately 9 weeks)</time_frame>
    <description>AUC of HRS9531 after multiple subcutaneous injections</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity qualitative</measure>
    <time_frame>Start of Treatment to end of study (approximately 9 weeks)</time_frame>
    <description>anti-HRS9531 antibody</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose concentration</measure>
    <time_frame>Start of Treatment to end of study (approximately 9 weeks)</time_frame>
    <description>fasting plasma glucose</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Single dose escalation of HRS9531 injection in healthy subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Single dose of placebo in healthy adults</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple dose escalation of HRS9531 injection in healthy subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple dose of placebo in healthy adults</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HRS9531</intervention_name>
    <description>Administered SC once</description>
    <arm_group_label>Single dose escalation of HRS9531 injection in healthy subjects</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Administered SC once</description>
    <arm_group_label>Single dose of placebo in healthy adults</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HRS9531</intervention_name>
    <description>Administered SC for multiple dose</description>
    <arm_group_label>Multiple dose escalation of HRS9531 injection in healthy subjects</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Administered SC for multiple dose</description>
    <arm_group_label>Multiple dose of placebo in healthy adults</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Ability to understand the trial procedures and possible adverse events, be able and&#xD;
             willing to provide a written informed consent;&#xD;
&#xD;
          2. Age 18-55 years on the date of signing informed consent (inclusive);&#xD;
&#xD;
          3. Body weight ≥50 kg, body mass index (BMI) within the range of 19.0-35.0 kg/m2&#xD;
             (inclusive);&#xD;
&#xD;
          4. Subjects with good general health, no clinically significant abnormalities.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. With previous major organ diseases, including but not limited to neuropsychiatric,&#xD;
             cardiovascular, digestive, respiratory, urinary, endocrine, blood, immune and other&#xD;
             diseases, are judged by researchers to be unsuitable for the study;&#xD;
&#xD;
          2. Had a severe trauma or major surgery within 6 months prior to screening, planned to&#xD;
             undergo surgery during the trial period;&#xD;
&#xD;
          3. Participants in clinical trials of any drug or medical device in the 3 months prior to&#xD;
             screening;&#xD;
&#xD;
          4. Blood donation history or blood loss ≥400 mL within 1 month before screening, or&#xD;
             received blood transfusion within 2 months;&#xD;
&#xD;
          5. Allergic constitution includes severe drug allergy or history of drug allergy;&#xD;
&#xD;
          6. Hepatitis B surface antigen (HBsAg), HIV antibody detection, treponema pallidum&#xD;
             specific antibody detection, hepatitis C virus antibody (HCVAb) positive;&#xD;
&#xD;
          7. Breast-feeding women;&#xD;
&#xD;
          8. The investigator considers that the subject has any other factors that would make it&#xD;
             inappropriate to participate in this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Luo Fei</last_name>
    <phone>18036618807</phone>
    <email>fei.luo@hengrui.com</email>
  </overall_contact>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 29, 2021</study_first_submitted>
  <study_first_submitted_qc>November 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 9, 2021</study_first_posted>
  <last_update_submitted>November 29, 2021</last_update_submitted>
  <last_update_submitted_qc>November 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

